Home › Funds › SECTOR GAMMA AS › SNDX
SECTOR GAMMA AS position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
SECTOR GAMMA AS reported holding 241,739 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$4.5M, representing 0.94% of its reported portfolio and ranking #32 among its reported holdings. SECTOR GAMMA AS has disclosed SNDX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SECTOR GAMMA AS's SNDX position evolved
SECTOR GAMMA AS first disclosed a stake in SNDX in Q3 2025 at 210,814 shares (US$3.2M). The position peaked in Q1 2026 at 286,007 shares, worth US$6.7M. Across 5 filings, SECTOR GAMMA AS increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 241,739 shares valued at US$4.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 210.81K | $3.24M | New |
| Q4 2025 | 252.06K | $5.30M | Add |
| Q1 2026 | 286.01K | $6.68M | Add |
| Q2 2026 | 241.74K | $5.28M | Reduce |
| Q3 2026 | 241.74K | $4.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $24.76M · Q3 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
More on SECTOR GAMMA AS
FAQ
How long has SECTOR GAMMA AS held SNDX?
SECTOR GAMMA AS has disclosed SNDX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is SECTOR GAMMA AS's current position in SNDX?
As of Q3 2026, SECTOR GAMMA AS holds 241.74K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $4.54M, representing 0.94% of its reported portfolio and ranking #32.
Has SECTOR GAMMA AS been buying or selling SNDX?
In the latest 13F filing (Q3 2026), SECTOR GAMMA AS held unchanged its position in SNDX. The position peaked in Q1 2026 at 286.01K shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.